| Property |
Value |
| Gene Symbol |
IL9 |
| Full Name |
Interleukin 9 |
| Chromosomal Location |
5q31.1 |
| NCBI Gene ID |
3568 |
| OMIM ID |
147931 |
| Ensembl ID |
ENSG00000145839 |
| UniProt ID |
P15248 |
| Encoded Protein |
Interleukin-9 (IL-9) |
| Protein Family |
Common gamma chain cytokine family |
| Protein Length |
144 amino acids |
| Molecular Weight |
~15 kDa |
| Associated Diseases |
Asthma, Allergic Disorders, Autoimmune Disease |
IL9 encodes Interleukin-9 (IL-9), a cytokine originally described in the late 1980s as a T cell-derived growth factor. IL-9 is now recognized as a Th2-associated cytokine that plays important roles in type 2 immune responses, allergic inflammation, and has emerging functions in the central nervous system (CNS).
IL-9 signals through a receptor complex consisting of IL9R and the common gamma chain (γc, encoded by IL2RG), which is shared with other cytokines including IL-2, IL-4, IL-7, IL-15, and IL-21. This shared receptor component explains some of the functional overlaps and interactions within the γc cytokine family.
The biological functions of IL-9 extend beyond its original description as a T cell growth factor. It is now known to:
- Promote Th2 cell differentiation and function
- Activate mast cells and enhance IgE production
- Support the survival and function of regulatory T cells
- Influence goblet cell differentiation and mucus production
- Act on various cells within the CNS
¶ Gene Structure and Evolution
The IL9 gene is located on chromosome 5q31.1 within the cytokine gene cluster. The gene spans approximately 4.5 kilobases and consists of 5 exons that encode a 144-amino acid secreted protein.
IL9 is evolutionarily conserved:
- Mus musculus (mouse) — 66% amino acid identity
- Rattus norvegicus (rat) — 64% identity
- Sus scrofa (pig) — 81% identity
The relatively lower conservation compared to some other cytokines suggests more rapid evolution, possibly driven by species-specific immune requirements.
¶ Protein Structure and Receptors
IL-9 shares structural features with other γc cytokines:
- Signal peptide (1-23 aa): Secretory signal
- Four-helix bundle (24-144 aa): Characteristic cytokine fold
- Disulfide bonds: Cys46-Cys81, Cys53-Cys117 for stability
The four-helix structure (A-D) follows the "up-up-down-down" topology typical of the cytokine family.
IL-9 signals through a heterodimeric receptor:
IL9R (IL-9 Receptor):
- Type I cytokine receptor
- Provides ligand specificity
- Expressed on various cell types including lymphocytes, mast cells, neurons, glia
Common gamma chain (γc, IL2RG):
- Shared by multiple cytokine receptors
- Required for signal transduction
- Expressed on most lymphocytes
The receptor is expressed on:
- T cells (particularly Th2)
- B cells
- Mast cells
- [Neurons](/cell-types- Microgliastrocytes
- Microglia
¶ CNS Expression and Functions
Within the CNS, IL-9 acts on multiple cell types:
Astrocyte responses:
- Induction of inflammatory mediators
- Promotion of astrocyte proliferation
- Potential roles in astrocyte-mediated neuroinflammation
Microglial effects:
- Modulation of microglial activation
- Regulation of cytokine production
- Potential neuroprotective or detrimental effects
IL-9 is elevated in AD and may contribute to disease processes:
- Increased brain expression in AD patients and models
- Astrocyte production — activated astrocytes produce IL-9
- Correlation with pathology — higher levels in regions with more severe pathology
- TH2 connection — type 2 immune responses in AD brain
Mechanisms involve:
- Enhancement of neuroinflammation through glial activation
- Potential effects on amyloid clearance
- Modulation of type 2 immune responses
In PD, IL-9 shows elevated expression and functional associations:
- Increased substantia nigra expression
- Dopaminergic neuron interactions — IL-9 may influence neuron viability
- Microglial activation — promotes inflammatory responses
- Potential dual roles — both pro-inflammatory and regulatory
The TH2 cytokine family, including IL-4, IL-5, IL-9, IL-13, has complex roles in neurodegeneration:
| Cytokine |
Pro-inflammatory |
Anti-inflammatory |
| IL-4 |
+ (some contexts) |
+++ (dominant) |
| IL-5 |
+ (eosinophils) |
++ |
| IL-9 |
++ |
+ (Treg support) |
| IL-13 |
+ |
++ |
This balance is important for understanding therapeutic targeting.
flowchart TD
A["IL-9 Cytokine"] --> B["IL9R + γc<br/>Receptor Complex"]
B --> C["JAK1 + JAK3<br/>Activation"]
C --> D["STAT3 + STAT5<br/>Phosphorylation"]
D --> E["Nuclear Translocation"]
E --> F["Gene Transcription"]
F --> G1["Cell Survival<br/>Proliferation"]
F --> G2["Cytokine Production"]
F --> G3["Effector Functions"]
G1 --> H1["T Cell Growth<br/>Th2 differentiation"]
G1 --> H2["Mast Cell Survival"]
G2 --> I1["Pro-inflammatory<br/>Cytokines"]
G2 --> I2["Chemokines"]
G3 --> J["Glial Activation<br/>Neuroinflammation"]
style A fill:#e1f5fe,stroke:#333
style B fill:#e1f5fe,stroke:#333
style F fill:#c8e6c9,stroke:#333
style J fill:#ffcdd2,stroke:#333
Several approaches are being explored:
| Strategy |
Approach |
Status |
| Anti-IL-9 antibodies |
Neutralize IL-9 |
Clinical trials |
| IL-9R antagonists |
Block receptor |
Preclinical |
| JAK inhibitors |
Block signaling |
Approved for some conditions |
| Th2 cell modulators |
Reduce source |
Various |
Asthma: Anti-IL-9 antibodies have been tested in severe asthma with mixed results
Autoimmune disease: IL-9 blockade may be beneficial in some autoimmune conditions
Neurodegeneration: Preclinical evidence suggests therapeutic potential in AD and PD
- Cytokine redundancy
- Complex roles (both pro- and anti-inflammatory)
- Species differences in receptor expression
IL9 is expressed in limited cell types:
| Cell Type |
Expression |
| Th2 cells |
High (activated) |
| Mast cells |
Moderate |
| Eosinophils |
Low to moderate |
| Innate lymphoid cells |
Moderate |
| Neurons |
Very low |
In the normal CNS:
- Minimal expression in neurons
- Low expression in glia
- Increases during inflammation
In disease states:
- Elevated in astrocytes
- Detected in microglia
- Found in CSF of patients
| Disease |
IL-9 Role |
| Asthma |
Promotes Th2 responses, airway hyperresponsiveness |
| Atopic dermatitis |
Contributes to skin inflammation |
| Food allergy |
Enhances IgE responses |
| Eosinophilic esophagitis |
Promotes eosinophil infiltration |
| Disease |
Evidence |
| Alzheimer's disease |
Elevated in brain, correlates with pathology |
| Parkinson's disease |
Elevated in substantia nigra |
| Multiple sclerosis |
Expressed in lesions |
¶ Receptor Complex and Activation
IL-9 signaling is initiated when the cytokine binds to its heterodimeric receptor complex comprising IL9R and the common gamma chain (γc, encoded by IL2RG). The γc chain is shared with IL-2, IL-4, IL-7, IL-15, and IL-21 receptors, creating potential for cross-talk and functional interactions 1.
The receptor complex activates:
- JAK1: Associated with IL9R
- JAK3: Associated with γc chain
- STAT3: Primary STAT activated
- STAT5: Secondary STAT pathway
¶ STAT Activation and Nuclear Signaling
STAT3 Pathway:
- Primary pathway for most IL-9 effects
- STAT3 dimers translocate to the nucleus
- Binds to GAS (γ-interferon activation sequence) elements
- Induces transcription of target genes including:
- Cytokine receptors (IL-9R itself)
- Anti-apoptotic proteins (Bcl-xL, Bcl-2)
- Cell cycle regulators
STAT5 Pathway:
- Contributes to lymphocyte survival
- Plays roles in mast cell function
- Modulates T cell differentiation
¶ PI3K-Akt and MAPK Pathways
Beyond JAK-STAT, IL-9 activates:
- PI3K-Akt pathway: Cell survival, metabolic regulation
- MAPK/ERK pathway: Cell proliferation and differentiation
- p38 pathway: Stress responses, cytokine production
IL-9 signaling is tightly controlled:
- SOCS proteins: SOCS1 and SOCS3 inhibit JAK activity
- Protein tyrosine phosphatases: Dephosphorylate signaling components
- Receptor internalization: Limits signal duration
- γc chain competition: Other cytokines can modulate signaling
IL-9 contributes to AD through multiple mechanisms 2:
Neuroinflammation:
- IL-9 activates astrocytes to produce inflammatory mediators
- Promotes microglial production of IL-1β, TNF-α, IL-6
- Creates chronic inflammatory environment
Type 2 Immune Responses:
- IL-9 is associated with Th2 responses in AD brain
- May compete with Th1/Th17 pro-inflammatory responses
- Complex regulatory effects on immunity
Potential Protective Effects:
- IL-9 can support regulatory T cells (Tregs)
- May have anti-inflammatory properties in some contexts
- The balance determines net effect
In PD, IL-9 has complex roles 3:
Dopaminergic Neuron Interactions:
- IL-9 receptors expressed on dopaminergic neurons
- May influence neuron survival and function
- Potential direct effects on vulnerable populations
Neuroinflammation:
- Promotes microglial activation in substantia nigra
- Contributes to inflammatory environment
- May accelerate progression
Therapeutic Implications:
- Blocking IL-9 may reduce neuroinflammation
- However, potential regulatory functions must be considered
- Requires careful targeting
IL-9 in MS/EAE has context-dependent roles 4:
Pro-inflammatory Effects:
- IL-9 in active lesions
- Promotes demyelination in some contexts
- Correlates with disease severity
Regulatory Functions:
- Supports Treg function
- May limit excessive inflammation
- Potential protective aspects
Mast cells are resident in the CNS and respond to IL-9 5:
- CNS location: Found in dura mater, leptomeninges, parenchyma
- IL-9 responsiveness: Express IL9R, respond to IL-9
- Mediator release: Histamine, serotonin, cytokines, proteases
The mast cell-neuron interface is relevant to neurodegeneration:
- Sensory innervation: Mast cells near nerve fibers
- Neurotrophic factors: Bidirectional signaling
- Neuroinflammation: Mast cell mediators affect neurons
Targeting the mast cell-IL-9 axis:
- Mast cell stabilizers: Reduce mediator release
- IL-9 blockade: Limits mast cell activation
- Combined approaches: Greater efficacy
¶ Regulatory T Cells and IL-9
IL-9 has important relationships with regulatory T cells 6:
- Treg survival: IL-9 supports Treg maintenance
- Function enhancement: IL-9 can enhance Treg suppressive activity
- Plasticity: Tregs may produce IL-9 in some contexts
In neurodegeneration:
- Tregs are often dysregulated
- IL-9 may help restore Treg function
- Balancing pro- and anti-inflammatory effects
¶ IL-9 vs IL-4 and IL-13
| Feature |
IL-9 |
IL-4 |
IL-13 |
| Receptor |
IL9R + γc |
IL4R + γc |
IL13R + γc |
| Th2 polarization |
++ |
+++ |
++ |
| B cell IgE |
+ |
+++ |
+++ |
| Eosinophils |
+ |
++ |
++ |
| Mast cells |
++ |
++ |
+ |
Despite sharing γc, IL-9 has distinct functions:
- IL-2: Broad T cell growth, survival
- IL-7: T cell development
- IL-15: NK cell function
- IL-21: B cell differentiation
- IL-9: Th2, mast cells, CNS functions
- Anti-IL-9 antibodies: Neutralize IL-9
- IL-9R antagonists: Block receptor binding
- JAK inhibitors: Broader cytokine blockade
- Mast cell targeting: Reduce effector cells
| Approach |
Stage |
Indication |
| Anti-IL-9 mAb |
Phase 2 |
Asthma, AD |
| JAK inhibitors |
Approved |
Autoimmune |
| Mast cell stabilizers |
Approved |
Allergy |
- Blood-brain barrier: Limited drug penetration
- Cytokine complexity: Network effects
- Dual roles: Both pro- and anti-inflammatory
- IL-9 knockout mice: Determine requirement
- IL-9 transgenic mice: Study overexpression
- Conditional knockouts: Cell-type specific
- Primary glial cultures: Glial responses
IL-9 as biomarker:
- CSF: Elevated in some neurodegenerative conditions
- Serum: Variable, less specific
- Correlation: With disease severity
- Cell-specific roles: Which cells are most important in CNS?
- Stage-specific effects: How does IL-9 change with disease progression?
- Therapeutic targeting: Can we achieve beneficial effects safely?
- Biomarker validation: Clinical utility?
- Single-cell analysis of IL-9 responses
- Structural studies of receptor complex
- Clinical trials in neurodegeneration
- Combination therapy approaches